SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, made a major impact on the group—and cardiology as a whole—over the last 12 months.
A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.
Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
Although advanced imaging exams have proven benefits in defining disease severity, new data indicate that more sophisticated studies might not impact outcomes as much as previously thought.
Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.
New research presented at the American College of Cardiology’s annual meeting has shown that long-term intermittent fasting improved outcomes for individuals with COVID-19 who also have a history of heart disease.
For patients who were hospitalized, but not yet in the ICU, those randomly assigned a higher-dose of anticoagulants had lower 30-day mortality risk than those on a lower dose.
Axillary lymphadenopathy following COVID vaccination and/or boosters is a finding all radiologists must be mindful of when interpreting imaging, but new data clarify the timeline for when the side effect should resolve.
The risk stratification system was put to the test in more than 3,000 cases and proved itself to be a beneficial tool in predicting future AVM rupture across multiple risk groups.
